Polverino Eva, Bothamley Graham H, Goletti Delia, Heyckendorf Jan, Sotgiu Giovanni, Aliberti Stefano
Fundació Clinic, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Ciber de Enfermedades Respiratorias, Barcelona, Spain; These authors contributed equally.
Dept of Respiratory Medicine, Homerton University Hospital, London, UK; These authors contributed equally.
ERJ Open Res. 2016 Jul 11;2(3). doi: 10.1183/23120541.00049-2016. eCollection 2016 Jul.
The breadth and quality of scientific presentations on clinical and translational research into respiratory infections at the 2015 European Respiratory Society (ERS) International Congress in Amsterdam, the Netherlands, establishes this area as one of the leadings fields in pulmonology. The host-pathogen relationship in chronic obstructive pulmonary disease, and the impact of comorbidities and chronic treatment on clinical outcomes in patients with pneumonia were studied. Various communications were dedicated to bronchiectasis and, in particular, to different prognostic and clinical aspects of this disease, including chronic infection with and inhaled antibiotic therapy. Recent data from the World Health Organization showed that Europe has the highest number of multidrug-resistant tuberculosis cases and the poorest countries have the least access to suitable treatments. Latent tuberculosis and different screening programmes were also discussed with particular attention to risk factors such as HIV infection and diabetes. Several biomarkers were proposed to distinguish between active tuberculosis and latent infection. Major treatment trials were discussed (REMOX, RIFQUIN and STREAM). The possibility of once-weekly treatment in the continuation phase (RIAQUIN) was especially exciting. The continuing rise of as a significant pathogen was noted. This article reviews some of the best contributions from the Respiratory Infections Assembly to the 2015 ERS International Congress.
在荷兰阿姆斯特丹举行的2015年欧洲呼吸学会(ERS)国际大会上,关于呼吸道感染临床和转化研究的科学报告的广度和质量,使该领域成为肺病学的前沿领域之一。研究了慢性阻塞性肺疾病中的宿主 - 病原体关系,以及合并症和长期治疗对肺炎患者临床结局的影响。各种交流致力于支气管扩张症,特别是该疾病的不同预后和临床方面,包括慢性感染和吸入抗生素治疗。世界卫生组织的最新数据显示,欧洲耐多药结核病病例数量最多,最贫穷国家获得适当治疗的机会最少。还讨论了潜伏性结核病和不同的筛查计划,特别关注诸如艾滋病毒感染和糖尿病等危险因素。提出了几种生物标志物以区分活动性结核病和潜伏感染。讨论了主要治疗试验(REMOX、RIFQUIN和STREAM)。继续期每周一次治疗(RIAQUIN)的可能性尤其令人兴奋。注意到作为重要病原体的[病原体名称未给出]持续增加。本文回顾了呼吸道感染大会对2015年ERS国际大会的一些最佳贡献。